Lead Product(s): Antisense OligoNucleotides
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Life Science Partners
Deal Size: $31.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 30, 2020
Vico will use this funding to further advance its late preclinical stage Antisense OligoNucleotides lead platform for the development of therapies for different forms of Spinocerebellar Ataxia (SCA) and Huntington Disease (HD) into first-in-human clinical trials in late 2021.